^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CO-1002

    i
    Other names: CO-1002
    Associations

    News

    Trials
    Company:
    Champions Oncology
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    Targeting tumor synthetic vulnerabilities and immune evasion mechanisms with CO-1002 (AACR 2023)
    A series of highly potent small molecule compounds were established against these targets using structure-based design, which shows robust in vitro and in vivo target engagement and favorable cytotoxic and phenotypic profiles across a large panel of cancer cell lines and PDXs. Collectively, this therapeutic program shows significant promise in treating a multitude of solid tumors as a monotherapy and in combination with currently approved immune therapies.
    BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    CO-1002